Medicament volatilization body and medicament volatilization device

Abstract

To provide a medicament volatilization body that can be held in a storage container in an appropriate state.SOLUTION: There is provided a medicament volatilization body 1 in which a volatile medicament is carried on a sheet-like carrier, which has a thickness of 0.01 to 2.5 mm and a penetration strength of 3.0 to 40.0 N when a rod having an outer diameter of φ3.0 mm is passed therethrough. There is provided the medicament volatilization body 1 in which a volatile medicament is carried on a sheet-like carrier, which has a thickness of 0.01 to 2.5 mm, a penetration strength exceeding 40.0 N when a rod having an outer diameter of φ3.0 mm is passed therethrough, and a bending resistance of 130 mm or less measured in accordance with the bending resistance (45° cantilever method) specified in JIS L1096:2020 "Testing methods for woven and knitted fabrics."SELECTED DRAWING: Figure 1

Description

[Technical Field]

[0001] The present invention relates to a drug volatilizer capable of volatilizing a volatile drug, and a drug volatilization device. [Background technology]

[0002] Conventionally, a drug volatilization device has been used in which a drug volatilizer, in which a volatile drug is impregnated into a carrier, is placed in a breathable container and installed at the location of use (e.g., entranceway, closet, outdoors, etc.) (see, for example, Patent Document 1).

[0003] In Patent Document 1, a housing (container body) divided into two in the thickness direction is used as a storage container, and vertical wall portions that can be butted together are provided at opposing positions on each housing.The drug volatilizer is held (fixed) by sandwiching it between these vertical wall portions (protruding portions), thereby forming a drug volatilization device (see Figure 10). [Prior art documents] [Patent documents]

[0004] [Patent Document 1] Japanese Patent Publication No. 2021-136917 Summary of the Invention [Problem to be solved by the invention]

[0005] When two upright walls are butted together and a drug volatilizer is held between them as in Patent Document 1, the holding force of the drug volatilizer is relatively low, and there is a risk of the holding becoming unstable. If the holding becomes unstable and the drug volatilizer becomes loose (falls off), the drug volatilizer may move unnecessarily inside the storage container, which may cause damage due to vibrations or a decrease in the amount of volatilized drug due to changes in posture.

[0006] In order to reliably hold the drug volatilizer, it is conceivable to increase the holding force of the drug volatilizer by the storage container. However, if the holding force of the drug volatilizer is increased too much, excessive load is placed on the drug volatilizer, which may cause breakage such as holes, tears, or rips in the drug volatilizer. On the other hand, if an attempt is made to increase the rigidity of the drug volatilizer in order to prevent such breakage, it may not be possible to fix (hold) the drug volatilizer inside the storage container, and the drug volatilizer may fall off.

[0007] The present invention has been made in consideration of the above circumstances, and aims to provide a drug volatilizer and a drug volatilization device that can be held in a storage container in an appropriate state. [Means for solving the problem]

[0008] The inventors of the present invention have conducted extensive research to solve the above problems, and have found that by setting the thickness and penetration strength of the drug volatilizer within an appropriate range, the drug volatilizer has appropriate rigidity, flexibility, and strength, and therefore, when held in a storage container, breakage due to friction, load, pulling, etc. is suppressed. Furthermore, they have found that the drug volatilizer can be firmly held in the storage container, thereby suppressing the drug volatilizer from falling off. Based on these findings, they have found that a drug volatilizer that can be held in a storage container in an appropriate state can be obtained, and have completed the present invention. Furthermore, it was found that when the thickness of the drug volatilizer is set within an appropriate range, even if the penetration strength is high, by setting the bending resistance to an appropriate small value, the drug volatilizer has appropriate rigidity, flexibility, and strength, and therefore, when held in a storage container, breakage due to friction, load, pulling, etc. was suppressed. It was also found that the drug volatilizer can be firmly held in the storage container, thereby suppressing the drug volatilizer from falling off, and based on these findings, it was found that a drug volatilizer that can be held in a storage container in an appropriate state can be obtained, leading to the completion of another present invention.

[0009] That is, the characteristic configuration of the drug volatilizer according to the present invention for solving the above problems is as follows: A drug volatilizer comprising a sheet-shaped carrier carrying a volatile drug, The thickness is 0.01 to 2.5 mm. The penetration strength, which is the strength when a rod with an outer diameter of φ3.0 mm is penetrated, is 3.0 to 40.0 N.

[0010] According to the drug volatilizer of this configuration, by setting its thickness and penetration strength within the above-mentioned appropriate range, the drug volatilizer has appropriate rigidity, flexibility, and strength, so that when held in a storage container, breakage due to friction, load, pulling, etc. is suppressed. Furthermore, since the drug volatilizer can be firmly held in the storage container, falling off of the drug volatilizer is suppressed. Therefore, the drug volatilizer can be held in the storage container in an appropriate state.

[0011] Another characteristic configuration of the drug volatilizer according to the present invention for solving the above problem is: A drug volatilizer comprising a sheet-shaped carrier carrying a volatile drug, The thickness is 0.01 to 2.5 mm. The penetration strength, which is the strength when a rod with an outer diameter of φ3.0 mm is penetrated, is more than 40.0 N, and The bending resistance measured in accordance with JIS L1096:2020 "Testing methods for woven and knitted fabrics" (45° cantilever method) is 130 mm or less.

[0012] According to the drug volatilizer of this configuration, even if the penetration strength is relatively high, exceeding 40.0 N, by setting the bending resistance to 130 mm or less, the drug volatilizer has the same rigidity, flexibility, and strength as when the penetration strength is 3.0 to 40.0 N, so that when held in a storage container, breakage due to friction, load, pulling, etc. is suppressed. Furthermore, since the drug volatilizer can be firmly held in the storage container, falling off of the drug volatilizer is suppressed. Therefore, the drug volatilizer can be held in the storage container in an appropriate state.

[0013] In the drug volatilizer of the present invention, The volatile agent preferably contains at least one active ingredient selected from the group consisting of metofluthrin, transfluthrin, profluthrin, and empenthrin.

[0014] According to the agent volatilizer of this configuration, the volatile agent contains the above-mentioned appropriate insecticidal component as an active ingredient, so that it can exert an insect repellent effect.

[0015] In the drug volatilizer of the present invention, The support preferably contains, as a constituent material, at least one selected from the group consisting of polyethylene, polypropylene, polyethylene terephthalate, polyvinyl chloride, ethylene vinyl acetate copolymer, ethylene methyl methacrylate copolymer, and acrylonitrile butadiene styrene copolymer.

[0016] According to the drug volatilizer of this configuration, by including the above-mentioned appropriate resin as a constituent raw material of the carrier, it becomes easier to set the thickness, penetration strength, and bending resistance of the drug volatilizer within the above-mentioned ranges.

[0017] In the drug volatilizer of the present invention, It is preferable that at least a portion of the volatile chemical is impregnated into the carrier.

[0018] With this configuration of drug volatilizer, at least a portion of the volatile drug is impregnated into the carrier, which allows the amount of volatile drug carried to be increased compared to other carrying means, such as coating, and therefore further enhances the effects derived from the volatile drug.

[0019] In the drug volatilizer of the present invention, The amount of the volatile drug carried on the support is 0.5 to 10 mg / cm 2 It is preferable that:

[0020] According to the drug volatilizer of this configuration, by setting the amount of volatile drug carried within the above-mentioned appropriate range, the effects derived from the volatile drug can be more appropriately exerted.

[0021] The characteristic configuration of another chemical volatilization device according to the present invention to solve the above problem is as follows: The drug volatilizer is held inside a container having an opening.

[0022] According to the drug volatilization device of this configuration, it is possible to provide a drug volatilization device in which the drug volatilization body is properly held inside the storage container.

[0023] In the drug volatilization device of the present invention, The storage container is configured by combining a first container body and a second container body that are divided into two in the thickness direction of the drug volatilizer, the first container body has a first protrusion protruding from the inside thereof, the second container body has a second protrusion protruding from the inside thereof, It is preferable that the first protrusion and the second protrusion are configured to sandwich the drug volatilizer.

[0024] According to the drug volatilization device of this configuration, the drug volatilization body can be more securely held inside the storage container by sandwiching the drug volatilization body between the first protrusion and the second protrusion.

[0025] In the drug volatilization device of the present invention, It is preferable that the first protrusion and the second protrusion are configured to sandwich the drug volatilizer in a bent state.

[0026] According to the drug volatilization device of this configuration, as described above, the drug volatilization body has appropriate rigidity, flexibility, and strength, so that even when it is clamped in a bent state under a relatively high load, breakage is suppressed. Furthermore, because the drug volatilization body is hooked on the first protrusion and the second protrusion, falling off of the drug volatilization body can be further suppressed.

[0027] In the drug volatilization device of the present invention, When the protruding length of the first protrusion is L1 (mm), the protruding length of the second protrusion is L2 (mm), and the distance between the inner surface of the portion of the first container body where the first protrusion is located and the inner surface of the portion of the second container body where the second protrusion is located is Ls (mm), it is preferable that the configuration is such that L1 + L2 - Ls is 0.05 to 5 (mm).

[0028] According to the drug volatilization device of this configuration, when the above L1+L2-Ls exceeds 0 (mm), the first protrusion and the second protrusion overlap each other in the protrusion direction. By setting the above L1+L2-Ls, which is a parameter indicating the degree of this overlap, within the above appropriate range, the drug volatilization body can be clamped with a more appropriate force. Furthermore, compared to when the drug volatilization body is not bent, the drug volatilization body can be clamped more firmly, thereby more effectively preventing the drug volatilization body from falling off. [Brief explanation of the drawings]

[0029] [Figure 1] FIG. 1 is a schematic perspective view of a drug volatilization device equipped with a drug volatilization body according to an embodiment of the present invention. [Figure 2] FIG. 2 is a schematic cross-sectional view showing an example of a cross section taken along the arrow AA in FIG. [Figure 3] FIG. 3 is a schematic cross-sectional view showing the measurement principle of a measuring device used in the penetration strength test and retention test. DETAILED DESCRIPTION OF THE INVENTION

[0030] The following describes the drug volatilizer and drug volatilizer of the present invention. However, the present invention is not intended to be limited to the configurations described in the embodiments described below. In addition, the configurations shown in the figures have been appropriately exaggerated or simplified to facilitate explanation, and the size and scale of each part may not accurately reflect the actual drug volatilizer and drug volatilizer.

[0031] [Drug volatilization body] Fig. 1 is a schematic perspective view of a drug volatilization device equipped with a drug volatilizer according to an embodiment of the present invention. Fig. 2 is a schematic cross-sectional view showing an example of a cross section taken along the arrow AA in Fig. 1, and Figs. 2(a), 2(c), and 2(d) are views showing examples of cross sections including the drug volatilizer, and Fig. 2(b) is a view showing an example of a cross section in Fig. 2(a) from which the drug volatilizer is omitted. The drug volatilizer 1 of this embodiment is held inside a storage container 20 having an opening 25 in the drug volatilization device 10.

[0032] The drug volatilizer 1 comprises a sheet-shaped carrier 2 carrying a volatile drug. The means for carrying the volatile drug on the carrier 2 is not particularly limited, but examples thereof include impregnation, kneading, and coating. Of these, impregnation or kneading is preferred. By impregnating or kneading at least a portion of the volatile drug into the carrier 2, the amount of the volatile drug carried can be increased compared to other carrying means, such as coating, and the effects derived from the volatile drug can be further enhanced.

[0033] <Volatile agents> The volatile agent is not particularly limited as long as it contains a volatile active ingredient. For example, the volatile agent may contain only the active ingredient, or may contain the active ingredient and other ingredients such as a solvent. Examples of the active ingredient include insecticidal ingredients, repellent ingredients, fragrance ingredients, deodorizing ingredients, antifungal ingredients, and antibacterial ingredients.

[0034] The insecticidal component is not particularly limited, but examples include pyrethroid insecticidal components such as transfluthrin, metofluthrin, empenthrin, profluthrin, allethrin, furamethrin, prallethrin, resmethrin, phthalthrin, fenothrin, and natural pyrethrins, organophosphorus insecticidal components such as dichlorvos, fenitrothion, and malathrin, and insect growth regulators such as methoprene and hydroprene. Some of these compounds may contain optical isomers or geometric isomers based on asymmetric carbons or unsaturated bonds, and it goes without saying that each of these, alone or in any mixture, is also encompassed in the active ingredient of the volatile agent of the present invention.

[0035] Repellent ingredients include, but are not limited to, 1-methylpropyl 2-(2-hydroxyethyl)-1-piperidinecarboxylate (icaridin), ethyl butylacetylaminopropionate (IR3535), N,N-diethyltoluamide (DEET), dimethyl phthalate, dibutyl phthalate, 2-ethyl-hexanediol, dibutyl succinate, p-menthane-3,8-diol, and the like.

[0036] The aromatic components are not particularly limited, but examples thereof include citronella oil, orange oil, lemon oil, lime oil, yuzu oil, lavender oil, peppermint oil, eucalyptus oil, jasmine oil, cypress oil, green tea essential oil, limonene, α-pinene, linalool, geraniol, phenylethyl alcohol, amyl cinnamic aldehyde, and benzyl acetate.

[0037] The deodorizing component is not particularly limited, but examples thereof include hiba oil, cypress oil, bamboo extract, mugwort extract, tung oil, pyruvic acid esters such as ethyl pyruvate and phenylethyl pyruvate.

[0038] The antifungal component is not particularly limited, but examples thereof include 2-n-octyl-4-isothiazolin-3-one, isopropylmethylphenol, and orthophenylphenol.

[0039] The antibacterial component is not particularly limited, but examples thereof include hinokitiol, tetrahydrolinalool, eugenol, citronellal, and allyl isothiocyanate.

[0040] Of these, the active ingredient of the volatile drug has a vapor pressure of 1.33322 x 10 at 30°C. -3 ~1.33322 Pa (1 mmHg = 133.322 Pa, converted to 1 x 10 -5 ~1×10 -2The pyrethroid compounds transfluthrin, metofluthrin, profluthrin, and empenthrin, which have a viscosity of 1000 psi (mmHg), are preferred. By selecting an appropriate insecticidal component as the active ingredient of the volatile agent, an insect repellent effect can be achieved. The active ingredient of the volatile agent can be any of the above components, either alone or as a mixture of two or more.

[0041] The amount of the volatile chemical carried on the support 2 is not particularly limited, but is preferably 0.5 to 10 mg / cm 2 By setting the amount of the volatile chemical to be carried within the above-mentioned appropriate range, the effects derived from the volatile chemical can be more appropriately exhibited.

[0042] <Support> The support 2 is sheet-shaped, can support a volatile chemical, and can volatilize the supported volatile chemical from its surface. It is not particularly limited, but examples thereof include resin films and nonwoven fabrics. The resin film may be either a non-stretched film or a stretched film, or a laminate thereof. It may also contain a filler. For example, a stretched film containing a filler may have voids formed around the filler by stretching. When the support 2 is a non-stretched film, the volatile chemical can be supported between the molecules of the resin constituting the film. When the support 2 is a stretched film containing a filler, the volatile chemical can be supported between the molecules of the resin constituting the film and in the voids around the filler. The nonwoven fabric may be made of natural fibers, synthetic fibers, or a combination thereof. When the support 2 is a nonwoven fabric, the volatile chemical can be supported in the voids within the fibers that make up the nonwoven fabric, and also in the voids between the fibers.

[0043] Examples of constituent materials for resin films and nonwoven fabrics include polyolefin resins such as polyethylene and polypropylene, polyester resins such as polyethylene terephthalate, acrylonitrile copolymers such as polyvinyl chloride, ethylene vinyl acetate copolymer, ethylene methyl methacrylate copolymer, and acrylonitrile butadiene styrene copolymer (copolymer), and polyamides such as nylon. Among these, polyethylene, polypropylene, polyethylene terephthalate, polyvinyl chloride, ethylene vinyl acetate copolymer, ethylene methyl methacrylate copolymer, and acrylonitrile butadiene styrene copolymer are preferred. By selecting the appropriate resin as the constituent material, it becomes easier to set the thickness and penetration strength of the drug volatilizer 1 within the appropriate range described below. The resin can be used alone or as a mixture of two or more types. The support 2 can be a single-layer structure using the above resin alone, or it can be a laminate structure using two or more types of resin.

[0044] The thickness of the support 2 is not particularly limited, but is set appropriately depending on the thickness of the drug volatilizer 1, and is preferably 0.01 to 2.5 mm, more preferably 0.01 to 2.0 mm, even more preferably 0.015 to 1.0 mm, and particularly preferably 0.02 to 0.09 mm. By setting the thickness of the support 2 within the above appropriate range, it becomes easier to set the thickness, penetration strength, and bending resistance of the drug volatilizer 1 within the appropriate ranges described below. It also becomes easier to set the amount of volatile drug carried within the above appropriate ranges.

[0045] The density (bulk) of the carrier 2 is not particularly limited, but is appropriately set depending on the density (bulk) of the drug volatilizer 1, and is 0.05 to 1.5 g / cm 3 is preferred, and 0.1 to 1.2 g / cm 3 More preferably, 0.7 to 1.1 g / cm 3 is more preferably 0.8 to 1.0 g / cm 3is particularly preferred. By setting the density (bulk) of the carrier 2 within the above-mentioned appropriate range, it becomes easier to set the thickness, penetration strength, and bending resistance of the drug volatilizer 1 within the appropriate ranges described below. In addition, it becomes easier to set the amount of volatile drug carried within the above-mentioned appropriate ranges.

[0046] The basis weight of the carrier 2 is not particularly limited, but is appropriately set depending on the basis weight of the chemical volatilizer 1, and is in the range of 5 to 250 g / m 2 is preferred, and 8 to 240 g / m 2 It is more preferable that the basis weight of the carrier 2 is set within the above-mentioned appropriate range, which makes it easier to set the thickness, penetration strength, and bending resistance of the chemical volatilizer 1 within the appropriate ranges described below. Also, it makes it easier to set the amount of volatile chemical carried within the above-mentioned appropriate ranges.

[0047] The bending resistance of the support 2 measured in accordance with JIS L1096:2020 "Testing methods for woven and knitted fabrics" (45° cantilever method) is not particularly limited, but is set appropriately depending on the bending resistance of the drug volatilizer 1, and is preferably 130 mm or less, more preferably 3 to 130 mm, even more preferably 10 to 100 mm, and particularly preferably 15 to 80 mm. By setting the bending resistance of the support 2 within the above appropriate range, it becomes easier to set the thickness, penetration strength, and bending resistance of the drug volatilizer 1 to the appropriate ranges described below.

[0048] <Characteristics of volatile chemicals> [Thickness] The thickness of the drug volatilizer 1 is 0.01 to 2.5 mm, preferably 0.01 to 2.0 mm, more preferably 0.015 to 1.0 mm, and even more preferably 0.02 to 0.09 mm. The thickness of the drug volatilizer 1 is approximately the same as the thickness of the support 2. Therefore, by appropriately adjusting the thickness of the support 2, the thickness of the drug volatilizer 1 can be set within the above range. In addition, it becomes easier to set the amount of volatile drug carried within the appropriate range described above.

[0049] [Density (bulk)] The density (bulk) of the drug volatilizer 1 is not particularly limited, but is preferably 0.05 to 1.5 g / cm 3 is preferred, and 0.1 to 1.2 g / cm 3More preferably, 0.7 to 1.1 g / cm 3 is more preferably 0.8 to 1.0 g / cm 3 is particularly preferred. By setting the density (bulk) of the drug volatilizer 1 within the above-mentioned appropriate range, the thickness, penetration strength, and bending resistance of the drug volatilizer 1 can be made appropriate. In addition, it becomes easier to set the amount of volatile drug carried within the above-mentioned appropriate range.

[0050] [Metsuke] The basis weight of the chemical volatilizer 1 is 5 to 250 g / m 2 is preferred, and 8 to 240 g / m 2 By setting the basis weight of the chemical volatilizer 1 within the above-mentioned appropriate range, the chemical volatilizer 1 will have more appropriate rigidity, flexibility, and strength. In addition, it becomes easier to set the amount of volatile chemical carried within the above-mentioned appropriate range.

[0051] [Penetration strength, bending resistance] The penetration strength and bending resistance of the drug volatilizer 1 can be set as in the following embodiment 1 and embodiment 2.

[0052] (Aspect 1) In the first embodiment, the penetration strength of the drug volatilizer 1, which is the strength when a rod having an outer diameter of 3.0 mm is penetrated, is 3.0 to 40.0 N, and preferably 3.0 to 36.0 N. Fig. 3(a) is a schematic cross-sectional view showing the measurement principle of the measuring device used in the penetration strength test. Referring to Fig. 3(a), the penetration strength is specifically measured by the following measurement method.

[0053] <Method for measuring penetration strength> As shown in Figure 3(a), a penetration strength testing device 50 is used, which is equipped with a measuring jig 51 consisting of a lower measuring jig 51a and an upper measuring jig 51b, and a rod 52. A drug volatilizer 1 is placed on the lower measuring jig 51a, which has a hole with an inner diameter of φ3.8 mm, and an upper measuring jig 51b, which has a hole with an inner diameter of φ3.8 mm, is placed on the drug volatilizer 1 in a position opposite the lower measuring jig 51a, and the drug volatilizer is sandwiched and fixed between the lower measuring jig 51a and the upper measuring jig 51b. In this state, a rod 52 having an outer diameter of 3.0 mm (specifically, a cylindrical rod having an outer diameter of 3.0 mm with a chamfered corner at the tip, the cylindrical portion having an outer diameter of 3.0 mm, and the truncated conical portion at the tip having an outer diameter of 3.0 mm at the bottom (connection portion with the cylindrical portion), an outer diameter of 2.5 mm at the top (tip surface), and a height (distance between the bottom and top surfaces) of 0.25 mm) is moved at a speed of 50±5 mm / min and passed through the hole in the upper measuring jig 51b, and the load (N) when the rod 52 penetrates the drug volatilizer 1 to the lower measuring jig 51a is taken as the penetration strength. Details of the method for measuring penetration strength will be described later.

[0054] By setting the penetration strength of the drug volatilizer 1 together with the thickness within the appropriate range, the drug volatilizer 1 has appropriate rigidity, flexibility, and strength, and is therefore less likely to break due to friction, load, pulling, etc. when held in the storage container 20. Furthermore, since the drug volatilizer 1 can be firmly held in the storage container 20, the drug volatilizer 1 is less likely to fall off. Therefore, the drug volatilizer 1 can be held in the storage container in an appropriate state.

[0055] In aspect 1, the bending resistance of the drug volatilizer 1 measured in accordance with JIS L1096:2020 "Testing methods for woven and knitted fabrics" (45° cantilever method) is not particularly limited as long as the drug volatilizer 1 satisfies the above-mentioned penetration strength, but is, for example, preferably 130 mm or less, more preferably 3 to 130 mm, even more preferably 10 to 100 mm, and particularly preferably 15 to 80 mm. By setting the bending resistance of the drug volatilizer 1 within the above-mentioned appropriate range, the drug volatilizer 1 can be held in a storage container in a more appropriate state.

[0056] (Aspect 2) In aspect 2, the drug volatilizer 1 has a penetration strength, which is the strength when a rod with an outer diameter of 3.0 mm is penetrated, of more than 40.0 N, as described above, and a bending resistance measured in accordance with JIS L1096:2020 "Testing Methods for Woven and Knit Fabrics" (45° cantilever method) of 130 mm or less. In this case, the penetration strength is preferably more than 40.0 N and less than 200 N, and more preferably more than 40.0 N and less than 170 N. The bending resistance is preferably 3 to 130 mm, more preferably 10 to 100 mm, and even more preferably 15 to 80 mm. The penetration strength is measured in the same manner as described above.

[0057] Even when the penetration strength of the drug volatilizer 1 is relatively high, exceeding 40.0 N, by setting the bending resistance to 130 mm or less, the drug volatilizer 1 has the same rigidity, flexibility, and strength as in embodiment 1, and therefore is less likely to break due to friction, load, pulling, etc. when held in a storage container. Furthermore, since the drug volatilizer 1 can be firmly held in the storage container, falling off of the drug volatilizer is suppressed. Therefore, the drug volatilizer can be held in the storage container in an appropriate state.

[0058] [Drug volatilization device] The drug volatilization device 10 has a drug volatilizer 1 held inside a storage container 20 having an opening 25. The drug volatilization device 10 may be provided with a handle 27. According to the drug volatilization device 10, the drug volatilizer 1 can be held inside the storage container 20 while suppressing breakage and falling off, so that the drug volatilizer 1 is properly held inside the storage container 20.

[0059] As shown in Figures 1 and 2, the storage container 20 is preferably configured by combining a first container body 21 and a second container body 23, which are divided into two in the thickness direction of the drug volatilizer 1 (the vertical direction in Figure 2). The first container body 21 has a first protrusion 22 protruding from its inside, and the second container body 23 has a second protrusion 24 protruding from its inside, and is preferably configured to sandwich the drug volatilizer 1 between the first protrusion 22 and the second protrusion 24. By sandwiching the drug volatilizer 1 between the first protrusion 22 and the second protrusion 24, the drug volatilizer 1 can be more securely held inside the storage container 20. The configurations of the first protrusion 22 and the second protrusion 24 are not particularly limited and can be set as appropriate.

[0060] For example, in the embodiment shown in Fig. 2(a), the first protrusion 22a (22) and the second protrusion 24a (24) are arranged opposite each other, and the second protrusion 24a is configured to be inserted into a recess of the tubular (e.g., cylindrical) first protrusion 22a. The first protrusion 22a can be, for example, columnar (e.g., cylindrical) as shown in Fig. 2(a), or can be other tubular (e.g., cylindrical) shapes.

[0061] For example, in the embodiment shown in Fig. 2(c), the first protrusion 22b (22) and the second protrusion 24b (24) are configured to be positioned so as not to face each other. The first protrusion 22b and the second protrusion 24b may be, for example, plate-shaped as shown in Fig. 2(c), or may be columnar, cylindrical, or the like.

[0062] In the embodiments shown in Figures 2(a) and 2(c), as shown in Figure 2(b), the sum L1 + L2 of the protrusion length L1 (mm) of the first protrusion 22 and the protrusion length L2 (mm) of the second protrusion 24 is preferably set to be greater than the distance Ls (mm) between the inner surface of the first container body 21 where the first protrusion 22 is located and the inner surface of the second container body 23 where the second protrusion 24 is located (L1 + L2 - Ls > 0). By setting the protrusions in this manner, the first protrusion 22 and the second protrusion 24 overlap in the protrusion direction (the vertical direction in Figures 2(a) to 2(c), i.e., the thickness direction of the drug volatilizer 1), thereby clamping the drug volatilizer 1 in a bent state. The drug volatilizer 1 has appropriate rigidity, flexibility, and strength, so that breakage is suppressed even when clamped in a bent state where a relatively high load is applied. Furthermore, since the drug volatilizer 1 is hooked on the first protruding portion 22 and the second protruding portion 24, it is possible to further prevent the drug volatilizer 1 from falling off. In this specification, the term "bent state" includes a state in which the drug volatilizer 1 is bent at an acute angle, a state in which it is bent at an obtuse angle, and a state in which it is twisted, and also includes a state in which the drug volatilizer 1 is bent while being subjected to an external load (for example, a pressing force, etc.).

[0063] The difference L1+L2-Ls between Ls and L1+L2 indicates the degree of overlap between the first protrusion 22 and the second protrusion 24, and it is preferable that this difference L1+L2-Ls is configured to be 0.05 to 5 (mm).

[0064] When the above L1+L2-Ls exceeds 0 (mm), the first protrusion 22 and the second protrusion 24 overlap each other in the protrusion direction. By setting the above L1+L2-Ls, which is a parameter indicating the degree of this overlap, within the appropriate range, the drug volatilizer 1 can be clamped with a more appropriate force. Furthermore, compared to when the drug volatilizer 1 is not bent as in the embodiment shown in Figure 2(d) described below, the drug volatilizer 1 can be clamped more firmly, thereby more effectively preventing the drug volatilizer 1 from falling off.

[0065] On the other hand, for example, in the embodiment shown in FIG. 2(d), the first protrusion 22c (22) and the second protrusion 24c (24) are arranged to face each other, with the tip of the first protrusion 22c butting against the tip of the second protrusion 24c. The first protrusion 22c and the second protrusion 24c can be, for example, columnar as shown in FIG. 2(d), or can be plate-shaped, cylindrical, or the like. In this embodiment, since the drug volatilizer 1 is interposed between the first protrusion 22c and the second protrusion 24c, the sum L1 + L2 of the protrusion length L1 of the first protrusion 22c and the protrusion length L2 of the second protrusion 24c is set to be smaller than the distance Ls between the inner surface of the portion of the first container body 21 where the first protrusion 22c is arranged and the inner surface of the portion of the second container body 23 where the second protrusion 24c is arranged (L1 + L2 - Ls < 0). Since the drug volatilizer 1 has appropriate rigidity, flexibility, and strength, in this embodiment, the drug volatilizer 1 can be firmly clamped with a relatively strong force. [Example]

[0066] EXAMPLES The present invention will be described in more detail below with reference to examples and comparative examples, but the present invention is not limited to these examples.

[0067] Example 1 According to the prescription shown in Table 1, Metofluthrin was used as a volatile agent, and by impregnating this into a polyethylene film with a thickness of 0.02 mm as a carrier, the content (carried amount) of the volatile agent was 1 mg / cm 2 A drug volatilization body was obtained. The thickness, density (bulk), and basis weight of the support of Example 1, as well as the thickness of the drug volatilization body, are shown in Table 1. The thickness of the drug volatilization body of Example 1 was the same as the thickness of the support.

[0068] (Examples 2 to 45, Comparative Examples 1 to 10) Drug volatilizers of Examples 2 to 45 and Comparative Examples 1 to 10 were obtained in the same manner as in Example 1, except that the formulations shown in Tables 1 to 8 were followed. The thickness, density (bulk), and basis weight of the support and the thickness of the drug volatilizer of Examples 2 to 45 and Comparative Examples 1 to 10 are shown in Tables 1 to 8. The thickness of the drug volatilizer of Examples 2 to 45 and Comparative Examples 1 to 10 was the same as the thickness of each support. In Table 7, P050SW-00X manufactured by Nippon Vilene Co., Ltd. was used as polypropylene nonwoven fabric 1, and P030UA-00X manufactured by Nippon Vilene Co., Ltd. was used as polypropylene nonwoven fabric 2. In Table 8, ED-17 manufactured by Tapyrus Co., Ltd. was used as polyolefin nonwoven fabric, and ETR-165 manufactured by Tapyrus Co., Ltd. was used as acrylic / polyolefin nonwoven fabric.

[0069] The drug volatilizers of Examples 1 to 45 and Comparative Examples 1 to 10 were subjected to the following bending resistance test, penetration strength test, and breakage suppression test. The results are shown in Tables 1 to 8.

[0070] [Bending resistance test] The bending resistance of the drug volatilizers of Examples 1 to 25, 31 to 38, 40 to 45, and Comparative Examples 1 to 10 was measured in accordance with the bending resistance (45° cantilever method) of JIS L1096:2020 "Testing Methods for Woven and Knit Fabrics." The results are shown in Tables 1 to 3 and 5 to 8. The bending resistance of the drug volatilizers of Examples 26 to 30 and 39 was not measured. Although not detailed here, the bending resistance of these drug volatilizers was the same as that of each carrier. Therefore, the bending resistance of the carrier before impregnation with the drug solution may be measured as the bending resistance of the drug volatilizer.

[0071] [Penetration strength test] As shown in Figure 3(a), a penetration strength test was carried out using a penetration strength tester 50 equipped with a measuring jig 51 consisting of a lower measuring jig 51a and an upper measuring jig 51b of the same shape, and a rod 52, to measure the penetration strength of the drug volatilizers of Examples 1 to 45 and Comparative Examples 1 to 10. Specifically, a drug volatilizer 1 was placed on a lower measuring jig 51a having a hole with an inner diameter of φ3.8 mm, and an upper measuring jig 51b having a hole with an inner diameter of φ3.8 mm was placed on the drug volatilizer 1 at a position opposite the lower measuring jig 51a, and the drug volatilizer was sandwiched and fixed between the lower measuring jig 51a and the upper measuring jig 51b. In this state, a rod 52 having an outer diameter of 3.0 mm (specifically, a cylindrical rod having an outer diameter of 3.0 mm with a chamfered tip corner, the cylindrical part having an outer diameter of 3.0 mm, and the truncated conical tip part having an outer diameter of 3.0 mm at the bottom (connection part with the cylindrical part), an outer diameter of 2.5 mm at the top (tip surface), and a height (distance between the bottom and top surfaces) of 0.25 mm) was attached to a push-pull gauge (standard type mechanical force gauge PS / PSS series model: PS-50N, manufactured by Imada Co., Ltd.), and the push-pull gauge was set to peak mode (when measuring in this mode, the pointer stops at the peak value (maximum value)). In this state, a motorized test stand (vertical motorized test stand Using a push-pull gauge (model: MV-500NII, manufactured by Imada Co., Ltd.), the rod 52 was moved at 50±5 mm / min and passed through the hole in the upper measuring jig 51b, and the maximum load (maximum load value) (N) was read when the drug volatilizer 1 penetrated the lower measuring jig 51a. This operation was performed three times, and the average value was taken as the penetration strength. If the load exceeded 50 N in these three operations, the load (kgf) was read three times in the same manner as above, except that a push-pull gauge (simple type mechanical force gauge FB / FS series, model: FB-20K, manufactured by Imada Co., Ltd.) was used instead of the push-pull gauge (PS-50). The average value (kgf) was multiplied by a coefficient of 9.8 to convert it into the penetration strength (N).

[0072] [Retention test] As shown in FIG. 3(b), a retention test was performed using a retention test device 60 equipped with a first evaluation jig 61 and a second evaluation jig 63. Specifically, a drug volatilizer 1 was placed and fixed on a first evaluation jig 61 having a cylindrical first evaluation protrusion 62 with an inner diameter of φ3.4 mm, an outer diameter of φ5.6 mm, and a protrusion length (height) of 2.4 mm. In this state, a second evaluation jig 63 having a cylindrical second evaluation protrusion 64 with an inner diameter of φ1.3 mm, an outer diameter of φ3.0 mm, and a protrusion length (height) of 2.4 mm was inserted into the recess (inside the cylinder) of the first evaluation jig 61 via the drug volatilizer 1 while moving at 50 ± 5 mm / min, and engaged. Then, the second evaluation jig 63 was pulled out from the first evaluation jig 61 and the engagement was released. After repeating this operation three times, it was judged according to the following evaluation criteria. Here, (1) if the first evaluation jig 61 and the second evaluation jig 63 can be engaged (interlocked) via the drug volatilizer 1, i.e., if the drug volatilizer 1 can be sandwiched and fixed (clamped) between the first evaluation jig 61 and the second evaluation jig 63, the drug volatilizer 1 can be held. On the other hand, if the drug volatilizer 1 gets in the way and the first evaluation jig 61 and the second evaluation jig 63 cannot be engaged via the drug volatilizer 1, the drug volatilizer 1 cannot be held. (2) Furthermore, when using the drug volatilizer 1 in real life, it is expected that the engagement operation may be repeated two or three times to check whether the drug volatilizer 1 is securely held. If breaks such as holes, tears, or rips occur in the drug volatilizer 1 starting from the engagement portion during these repeated engagement operations, the drug volatilizer 1 cannot be securely held. Taking into account the above (1) and (2), the retention of the drug volatilizer 1 was evaluated using the following evaluation criteria. (Evaluation criteria) Good: The drug volatilizer can be clamped between the first evaluation jig and the second evaluation jig during each engagement operation, and no holes, tears, rips, or other damage is observed in the drug volatilizer even when the engagement operation is repeated. Poor: During the three repeated engagement operations, holes, tears, ruptures, etc. were observed in the drug volatilizer (poor 1), or the drug volatilizer could not be retained during each engagement operation (poor 2).

[0073]

Table 1

[0074]

Table 2

[0075]

Table 3

[0076]

Table 4

[0077]

Table 5

[0078]

Table 6

[0079]

Table 7

[0080]

Table 8

[0081] As shown in Tables 1 to 4 and 7, the drug volatilizers of Examples 1 to 39, which had thicknesses of 0.01 to 2.5 mm and penetration strengths of 3.0 to 40.0 N, were able to be clamped between the first evaluation jig and the second evaluation jig during each of three engagement operations, and no breakage was observed even after repeating the above operation three times. Therefore, it was demonstrated that the drug volatilizers of Examples 1 to 39 have appropriate rigidity, flexibility, and strength, and are firmly held in the storage container, and breakage due to friction, load, pulling, etc. is also suppressed. It was also demonstrated that such effects can be exerted regardless of the type of carrier, such as film or nonwoven fabric. Furthermore, it is reasonably assumed that the drug volatilizer can be firmly held in the storage container, thereby suppressing its detachment.

[0082] In contrast, as shown in Tables 5 and 6, the drug volatilizers of Comparative Examples 1 to 5, which had a thickness of 0.01 to 2.5 mm but a penetration strength below the lower limit of 3.0 to 40.0 N, were found to break within three repetitions of the above procedure, indicating that they did not have adequate rigidity, flexibility, and strength, and that breakage due to friction, load, pulling, etc. was not suppressed when held in a storage container. Therefore, it is reasonably assumed that the drug volatilizer could not be firmly held in the storage container, and that falling off of the drug volatilizer was not suppressed. The drug volatilizers of Comparative Examples 6 to 10, which had a thickness of 0.01 to 2.5 mm but a penetration strength above the upper limit of 3.0 to 40.0 N, were unable to engage the second evaluation protrusion of the second evaluation jig with the recess (inside the cylinder) of the first evaluation jig, and were therefore unable to hold the drug volatilizer 1 in the first place.

[0083] The drug volatilizers of Comparative Examples 6 to 10 not only had a penetration strength exceeding the upper limit of 3.0 to 40.0, but also had a bending resistance of 150 mm, exceeding 130 mm.

[0084] In contrast, as shown in Table 8, even when the thickness was within the range of 0.01 to 2.5 mm but the penetration strength exceeded the upper limit of 3.0 to 40.0 N (over 40.0 N), Examples 40 to 45, in which the bending resistance of the drug carrier was 130 mm or less, were able to sandwich the drug volatilizer between the first evaluation jig and the second evaluation jig during each of the three engagement operations, and no breakage was observed even after repeating the above operation three times. Therefore, it was shown that the drug volatilizers of Examples 40 to 45 have appropriate rigidity, flexibility, and strength, and are firmly held when held in a storage container, and breakage due to friction, load, pulling, etc. is also suppressed. It was also shown that such an effect can be exerted regardless of the type of carrier, such as a film or nonwoven fabric. Furthermore, it is reasonably assumed that the drug volatilizer can be firmly held in the storage container, thereby suppressing its detachment. [Industrial Applicability]

[0085] The drug volatilizer and drug volatilization device of the present invention can be used to volatilize volatile drugs (e.g., insecticidal components, repellent components, fragrance components, deodorizing components, antifungal components, antibacterial components, etc.) at the place of use (e.g., entrance hall, closet, outdoors, etc.). [Explanation of symbols]

[0086] 1. Drug volatilization 2. Support 10 Chemical vaporizer 20 Containment Container 21 First container body 22, 22a, 22b, 22c First protrusion 23 Second container body 24, 24a, 24b, 24c Second protrusion 25 Opening 50 Penetration Strength Testing Device 51 Measuring Jig 51a Lower measuring jig 51b Upper measuring jig 52 bars

Claims

1. A drug volatilizer comprising a sheet-shaped carrier carrying a volatile drug, The thickness is 0.01 to 2.5 mm, A drug volatilizer having a penetration strength of 3.0 to 40.0 N when penetrated by a rod with an outer diameter of φ3.0 mm.

2. A drug volatilizer comprising a sheet-shaped carrier carrying a volatile drug, The thickness is 0.01 to 2.5 mm, The penetration strength, which is the strength when a rod with an outer diameter of φ3.0 mm is penetrated, is more than 40.0 N, and A drug volatile material having a bending resistance of 130 mm or less as measured in accordance with JIS L1096:2020 "Testing methods for woven and knitted fabrics" (45° cantilever method).

3. The volatile drug volatilizer according to claim 1 or 2, wherein the volatile drug contains at least one selected from the group consisting of metofluthrin, transfluthrin, profluthrin, and empenthrin as an active ingredient.

4. The drug volatilizer described in claim 1 or 2, wherein the carrier contains at least one selected from the group consisting of polyethylene, polypropylene, polyethylene terephthalate, polyvinyl chloride, ethylene vinyl acetate copolymer, ethylene methyl methacrylate copolymer, and acrylonitrile butadiene styrene copolymer as a constituent material.

5. 3. A drug volatilizer as described in claim 1 or 2, wherein at least a portion of the volatile drug is impregnated into the carrier.

6. The amount of the volatile drug carried on the carrier is 0.5 to 10 mg / cm ２ The drug volatilizer according to claim 5, which is

7. A drug volatilization device comprising the drug volatilizer according to claim 1 or 2 held inside a container having an opening.

8. The storage container is configured by combining a first container body and a second container body that are divided into two in the thickness direction of the drug volatilizer, the first container body has a first protrusion protruding from the inside thereof, the second container body has a second protrusion protruding from the inside thereof, A drug volatilization device as described in claim 7, configured to sandwich the drug volatilizer between the first protrusion and the second protrusion.

9. The drug volatilization device of claim 8, wherein the first protrusion and the second protrusion are configured to clamp the drug volatilization body in a bent state.

10. The drug volatilization device of claim 9 is configured such that, when the protruding length of the first protrusion is L1 (mm), the protruding length of the second protrusion is L2 (mm), and the distance between the inner surface of the portion of the first container body where the first protrusion is located and the inner surface of the portion of the second container body where the second protrusion is located is Ls (mm), L1 + L2 - Ls is 0.05 to 5 (mm).

Images